Login/Register
  • 中文
  • English

News

Bora Pharmaceuticals Subsidiary Expands Footprint in Mainland China

Bora Pharmaceuticals announced on December 9 that its subsidiary Bora Health’s proprietary product, Megestrol Acetate Oral Suspension, has been included in the China National Reimbursement Drug List (NRDL).

Read more
Dec 10, 2025
Adimmune Subsidiary Enimmune Partners with Thermo Fisher for Allergy Markets
Dec 09, 2025
Taipei Veterans General Hospital (TVGH) Showcases AI and Robotics: Mapping the Future Healthcare Blueprint
Dec 09, 2025
Immunwork Completes Clinical Trial for Obesity Drug: Demonstrates Safety and Efficacy
Dec 09, 2025
Pharmosa BiopharmInitiates Global Phase 3 for L606: Superior Data Accelerates Dual Indications
Dec 09, 2025
Handa Pharmaceuticals to List on Mainboard Dec 23; Dual Engines Drive Profit Growth
Dec 08, 2025
Taiwan’s SNQ Certification Goes Global, Setting Asia-Pacific Standards with ICHOM
Dec 08, 2025
Taiwan Healthcare+ Expo Integrates with Global Markets
Dec 08, 2025
Gongwin-KY Becomes First Taiwan-Listed Firm in China’s Commercial Insurance Innovative Drug Catalog
Dec 08, 2025
OBI Pharma’s OBI-902 Secures Second U.S. FDA Orphan Drug Designation for Gastric Cancer

Most Watched

Recommended

TRIO.BAS DUO cable Dual-Head Microbial Air Sampler
ABUNDANT LIFE CO., LTD.
TED-22 Orthopedic Carbon Fiber Extension Device
BenQ Group
New cell drug company on all therapies
Ever Supreme Bio Technology Co.,Ltd.

Industry Watch

Read more